<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157971">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01750593</url>
  </required_header>
  <id_info>
    <org_study_id>yelizeminersoy</org_study_id>
    <nct_id>NCT01750593</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation in Thyroid Nodules</brief_title>
  <official_title>Efficacy of Radiofrequency Ablation in Thyroid Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bezmialem Vakif University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bezmialem Vakif University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thyroid nodules are common problems and although &gt; 95% are stated to be benign, they may
      cause some problems like hyperthyroidism, compression symptoms, and cosmesis associated with
      their function, size and localization. Especially for these nodules, patients undergo
      surgery and face up with the problems associated with surgical complications although they
      are not cancer. In some studies, radiofrequency ablation previously used for intrabdominal
      tumors like hepatic metastasis...,was stated to be efficient in the treatment of benign
      thyroid nodules and in some recurrent thyroid cancer cases. Therefore, the investigators
      decided to use this method in our patients having nodules like previously mentioned and see
      the efficacy and safety of the technique.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Shrinkage of the thyroid nodule after radiofrequency ablation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disappearance of the nodules in follow up</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid Nodules</condition>
  <arm_group>
    <arm_group_label>radiofrequency ablation of thyroid nodule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation of the thyroid nodule</intervention_name>
    <description>Under USG control,  the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.</description>
    <arm_group_label>radiofrequency ablation of thyroid nodule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. the presence of subjective symptoms (foreign body sensation, neck discomfort or pain,
             compressive symptom) or cosmetic problems;

          2. a poor surgical candidate or refusal to undergo surgery;

          3. fine-needle aspiration cytology and US findings that were compatible with a benign
             nodule;

          4. anxiety about a malignancy.

        Exclusion Criteria:

          1. a nodule less than 5 mm in size;

          2. follicular neoplasm or malignancy on fine needle aspiration cytology (FNAC);

          3. a nodule with the sonographic criteria for a malignancy (taller than wide, marked
             hypoechoic, microcalcifications, ill-defined margins), although FNAC was a benign
             result;

          4. previous radiation or operation history to the head and neck; (5) previous sclerosing
             therapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erhan Aysan, Prof. Dr.</last_name>
    <email>erhanaysan@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yeliz Ersoy, Assoc.Prof</last_name>
    <email>yelizemineersoy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bezmialem Vakif University medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <zip>34308</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhan Aysan, Prof. Dr.</last_name>
      <email>erhanaysan@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakif University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERHAN AYSAN, PROF.</last_name>
      <phone>902124531700</phone>
      <email>yelizemineersoy@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakif University</name>
      <address>
        <city>Istanbul</city>
        <zip>34308</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhan Aysan, Prof</last_name>
      <phone>902124531700</phone>
      <phone_ext>4116</phone_ext>
      <email>erhanaysan@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yeliz Ersoy, Assoc. Prof</last_name>
      <phone>902124531700</phone>
      <phone_ext>4506</phone_ext>
      <email>yelizemineersoy@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>October 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bezmialem Vakif University</investigator_affiliation>
    <investigator_full_name>Yeliz Emine Ersoy</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>radiofrequency</keyword>
  <keyword>thyroid</keyword>
  <keyword>nodule</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Nodule</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
